Tags

Type your tag names separated by a space and hit enter

Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium.
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17; 33(2):235-42.PN

Abstract

Literature data has shown that acute administration of magnesium reduces immobility time in the mouse forced swimming test (FST), which suggests potential antidepressant activity in humans. However, its mechanism of action is not completely understood. Thus, this study is aimed at investigating the antidepressant-like action of magnesium and the possible involvement of the monoaminergic system in its effect in the FST. The immobility time in the FST was significantly reduced by magnesium chloride administration (30-100 mg/kg, i.p.) without accompanying changes in ambulation when assessed in an open-field test. The pre-treatment of mice with NAN-190 (0.5 mg/kg, i.p. a 5-HT(1A) receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT(1A) receptor antagonist), ritanserin (4 mg/kg, i.p., a 5-HT(2A/2C) receptor antagonist), ketanserin (5 mg/kg, a preferential 5-HT(2A) receptor antagonist), prazosin (1 mg/kg, i.p., an alpha(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an alpha(2)-adrenoceptor antagonist), haloperidol (0.2 mg/kg, i.p., a non selective dopaminergic receptor antagonist), SCH23390 (0.05 mg/kg, s.c., a dopamine D(1) receptor antagonist) or sulpiride (50 mg/kg, i.p., a dopamine D(2) receptor antagonist) 30 min before the administration of magnesium chloride (30 mg/kg, i.p.) significantly prevented its anti-immobility effect in the FST. Moreover, the administration of sub-effective doses of fluoxetine (10 mg/kg, i.p., serotonin reuptake inhibitor), imipramine (5 mg/kg, i.p., a mixed serotonergic noradrenergic reuptake inhibitor), bupropion (1 mg/kg, i.p., dopamine reuptake inhibitor) was able to potentiate the action of sub-effective doses of magnesium chloride. In conclusion, the present study provides evidence indicating that the antidepressant-like effect of magnesium in the FST is dependent on its interaction with the serotonergic (5-HT(1A) and 5-HT(2A/2C) receptors), noradrenergic (alpha(1)- and alpha(2)- receptors) and dopaminergic (dopamine D(1) and D(2) receptors) systems.

Authors+Show Affiliations

Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, 88040-900, Florianópolis-SC, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19059299

Citation

Cardoso, Chandra C., et al. "Evidence for the Involvement of the Monoaminergic System in the Antidepressant-like Effect of Magnesium." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 33, no. 2, 2009, pp. 235-42.
Cardoso CC, Lobato KR, Binfaré RW, et al. Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):235-42.
Cardoso, C. C., Lobato, K. R., Binfaré, R. W., Ferreira, P. K., Rosa, A. O., Santos, A. R., & Rodrigues, A. L. (2009). Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Progress in Neuro-psychopharmacology & Biological Psychiatry, 33(2), 235-42. https://doi.org/10.1016/j.pnpbp.2008.11.007
Cardoso CC, et al. Evidence for the Involvement of the Monoaminergic System in the Antidepressant-like Effect of Magnesium. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):235-42. PubMed PMID: 19059299.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. AU - Cardoso,Chandra C, AU - Lobato,Kelly R, AU - Binfaré,Ricardo W, AU - Ferreira,Priscilla K, AU - Rosa,Angelo O, AU - Santos,Adair Roberto S, AU - Rodrigues,Ana Lúcia S, Y1 - 2008/11/27/ PY - 2008/09/05/received PY - 2008/10/25/revised PY - 2008/11/14/accepted PY - 2008/12/9/pubmed PY - 2009/6/3/medline PY - 2008/12/9/entrez SP - 235 EP - 42 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog Neuropsychopharmacol Biol Psychiatry VL - 33 IS - 2 N2 - Literature data has shown that acute administration of magnesium reduces immobility time in the mouse forced swimming test (FST), which suggests potential antidepressant activity in humans. However, its mechanism of action is not completely understood. Thus, this study is aimed at investigating the antidepressant-like action of magnesium and the possible involvement of the monoaminergic system in its effect in the FST. The immobility time in the FST was significantly reduced by magnesium chloride administration (30-100 mg/kg, i.p.) without accompanying changes in ambulation when assessed in an open-field test. The pre-treatment of mice with NAN-190 (0.5 mg/kg, i.p. a 5-HT(1A) receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT(1A) receptor antagonist), ritanserin (4 mg/kg, i.p., a 5-HT(2A/2C) receptor antagonist), ketanserin (5 mg/kg, a preferential 5-HT(2A) receptor antagonist), prazosin (1 mg/kg, i.p., an alpha(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an alpha(2)-adrenoceptor antagonist), haloperidol (0.2 mg/kg, i.p., a non selective dopaminergic receptor antagonist), SCH23390 (0.05 mg/kg, s.c., a dopamine D(1) receptor antagonist) or sulpiride (50 mg/kg, i.p., a dopamine D(2) receptor antagonist) 30 min before the administration of magnesium chloride (30 mg/kg, i.p.) significantly prevented its anti-immobility effect in the FST. Moreover, the administration of sub-effective doses of fluoxetine (10 mg/kg, i.p., serotonin reuptake inhibitor), imipramine (5 mg/kg, i.p., a mixed serotonergic noradrenergic reuptake inhibitor), bupropion (1 mg/kg, i.p., dopamine reuptake inhibitor) was able to potentiate the action of sub-effective doses of magnesium chloride. In conclusion, the present study provides evidence indicating that the antidepressant-like effect of magnesium in the FST is dependent on its interaction with the serotonergic (5-HT(1A) and 5-HT(2A/2C) receptors), noradrenergic (alpha(1)- and alpha(2)- receptors) and dopaminergic (dopamine D(1) and D(2) receptors) systems. SN - 0278-5846 UR - https://www.unboundmedicine.com/medline/citation/19059299/Evidence_for_the_involvement_of_the_monoaminergic_system_in_the_antidepressant_like_effect_of_magnesium_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(08)00358-8 DB - PRIME DP - Unbound Medicine ER -